Fig S1.
Fig S2.

A

soluble mouse CD137 (pg/ml) in plasma

Days

3 6 9 12

B

Tumor size (mm²)

Days

0 10 20 30

C

soluble mouse CD137 (pg/ml) in plasma

Days

3 6 9 12

B16-F10

LLC

Rat IgG (i.p.) w/o Tumor

Rat IgG (i.t.)

3H3 (i.p.) w/o Tumor

3H3 (i.t.)
Fig S3.

A

B

C  Human

D  Mouse

CD137 MFI

CD26 MFI

CD69 MFI

%K67+

Granzyme B MFI

rh-1BB (µg/ml) 0 0.01 0.1 1 10

rh-1BB (µg/ml) 0 0.01 0.1 1 10

rh-1BB (µg/ml) 0 0.01 0.1 1 10

rmk-1BB (µg/ml) 0 0.01 0.1 1 10

rmk-1BB (µg/ml) 0 0.01 0.1 1 10

Donor 1

Donor 2

Donor 3

Mouse 1

Mouse 2

Mouse 3
Fig S4.

A

B

Fig S5.

A

<table>
<thead>
<tr>
<th>Donor</th>
<th>M11 28z</th>
<th>M11 BBz</th>
<th>Untransduced</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>40.88%</td>
<td>29.92%</td>
<td>41.38%</td>
</tr>
<tr>
<td>2</td>
<td>38.12%</td>
<td>19.26%</td>
<td>22.18%</td>
</tr>
<tr>
<td>3</td>
<td>37.36%</td>
<td>26.56%</td>
<td>19.26%</td>
</tr>
<tr>
<td>4</td>
<td>38.12%</td>
<td>19.26%</td>
<td>22.18%</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>aMesothelin-PE</td>
</tr>
</tbody>
</table>

Supplemental material placed on this supplemental material which has been supplied by the author(s)

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance

J Immunother Cancer
doi: 10.1136/jitc-2021-003532